Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rifampicin
Drug ID BADD_D01936
Description A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Indications and Usage For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
Marketing Status approved
ATC Code J04AB02
DrugBank ID DB01045
KEGG ID D00211
MeSH ID D012293
PubChem ID 135398735
TTD Drug ID D0G3DL
NDC Product Code 73005-0006
UNII VJT6J7R4TR
Synonyms Rifampin | Benemycin | Rifampicin | Rimactan | Tubocin | Rifadin | Rimactane
Chemical Information
Molecular Formula C43H58N4O12
CAS Registry Number 13292-46-1
SMILES CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C) OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Death08.04.01.001--
Delirium19.13.02.0010.001867%
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001867%
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.001867%Not Available
Drug hypersensitivity10.01.01.0010.028185%Not Available
Drug interaction08.06.03.0010.030612%Not Available
Dry skin23.03.03.0010.006346%
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.0040.008773%
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.0010.005973%
Epistaxis22.04.03.001; 24.07.01.0050.005040%
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flank pain08.01.08.007; 20.02.03.006; 15.03.04.0030.001867%
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Gingival bleeding07.09.07.001; 24.07.02.0100.002800%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene